Staging and evaluation of neoadjuvant chemotherapy response with F-18-FDG PET/CT in NUT-midline carcinoma in a child: A case report and review of the literature

ÇİFTÇİ E., DEMİRSOY U., ANIK Y., Gorur G., Corapcioglu F., DEMİR H.

REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, vol.34, no.1, pp.53-55, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 1
  • Publication Date: 2015
  • Doi Number: 10.1016/j.remn.2014.08.007
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.53-55
  • Keywords: NUT midline carcinoma, F-18-FDG PET/CT, Children, Response evaluation, FEATURES
  • Kocaeli University Affiliated: Yes


NUT midline carcinoma (NMC) is a newly defined and lethal cancer with aggressive course. It mostly affects children and young adults. Diagnosis is confirmed with the evidence of BRD4-NUT mutation on the chromosome 15q14 by fluorescence in situ hybridization. Use of F-18-FDG PET/CT in NMC patients is very limited in the literature. In this report, we describe a 7-year-old boy with the diagnosis of NMC who was scanned with F-18-FDG PET/CT for staging and treatment response evaluation after the chemotherapy. It was disseminated and had moderate FDG avidity in the initial scan and showed progression after 4 cycles of chemotherapy. We also reviewed the literature related to F-18-FDG PET/CT in staging and assessment of chemotherapy response of NMC. (C) 2014 Elsevier Espana, S.L.U. and SEMNIM. All rights reserved.